MX361375B - Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano. - Google Patents
Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano.Info
- Publication number
- MX361375B MX361375B MX2015011385A MX2015011385A MX361375B MX 361375 B MX361375 B MX 361375B MX 2015011385 A MX2015011385 A MX 2015011385A MX 2015011385 A MX2015011385 A MX 2015011385A MX 361375 B MX361375 B MX 361375B
- Authority
- MX
- Mexico
- Prior art keywords
- tryptophan
- inhibitors
- treating
- metabolization
- tricyclic compounds
- Prior art date
Links
- 206010062016 Immunosuppression Diseases 0.000 title abstract 3
- 230000001506 immunosuppresive effect Effects 0.000 title abstract 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title abstract 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 abstract 1
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 abstract 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784089P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/022680 WO2014159248A1 (en) | 2013-03-14 | 2014-03-10 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015011385A MX2015011385A (es) | 2016-02-03 |
| MX361375B true MX361375B (es) | 2018-12-05 |
Family
ID=50686105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011385A MX361375B (es) | 2013-03-14 | 2014-03-10 | Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9617272B2 (https=) |
| EP (2) | EP2976332B1 (https=) |
| JP (2) | JP6093903B2 (https=) |
| KR (1) | KR20150126623A (https=) |
| CN (1) | CN105189466A (https=) |
| AU (2) | AU2014241079C1 (https=) |
| BR (1) | BR112015022588A2 (https=) |
| CA (1) | CA2902174A1 (https=) |
| CL (2) | CL2015002649A1 (https=) |
| CR (1) | CR20150485A (https=) |
| IL (1) | IL241027A0 (https=) |
| MA (1) | MA38493B1 (https=) |
| MX (1) | MX361375B (https=) |
| PE (1) | PE20151593A1 (https=) |
| PH (1) | PH12015501866A1 (https=) |
| RU (1) | RU2667509C2 (https=) |
| SA (1) | SA515361127B1 (https=) |
| SG (2) | SG11201507255QA (https=) |
| UA (1) | UA118103C2 (https=) |
| WO (1) | WO2014159248A1 (https=) |
| ZA (1) | ZA201607948B (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調節劑 |
| WO2014152537A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
| PE20151727A1 (es) | 2013-03-14 | 2015-12-17 | Boehringer Ingelheim Int | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c |
| TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| ES2654288T3 (es) | 2013-03-14 | 2018-02-13 | Janssen Pharmaceutica, N.V. | Moduladores de P2X7 |
| CN103570727B (zh) | 2013-11-12 | 2015-08-19 | 复旦大学 | 一种n-苄基色胺酮衍生物及其制备方法和应用 |
| SG10201804868PA (en) * | 2014-09-05 | 2018-07-30 | Merck Patent Gmbh | Compounds for the inhibition of indoleamine-2,3-dioxygenase |
| WO2016039983A1 (en) | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulating n-acyl-triazolopyrazines |
| KR102510588B1 (ko) | 2014-09-12 | 2023-03-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 카텝신 c의 스피로사이클릭 억제제 |
| CA2960968A1 (en) | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulators |
| GB201417369D0 (en) * | 2014-10-01 | 2014-11-12 | Redx Pharma Ltd | Compounds |
| US20160145344A1 (en) * | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
| RU2719446C2 (ru) | 2014-11-03 | 2020-04-17 | Айомет Фарма Лтд | Фармацевтическое соединение |
| US10525035B2 (en) | 2014-12-18 | 2020-01-07 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
| CN105884828A (zh) * | 2015-02-16 | 2016-08-24 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| JP6806342B2 (ja) * | 2015-04-10 | 2021-01-06 | ベイジーン リミテッド | インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ |
| JP2018511647A (ja) | 2015-04-12 | 2018-04-26 | ハンジョウ イノゲート ファーマ カンパニー リミテッドＨａｎｇｚｈｏｕ Ｉｎｎｏｇａｔｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | Ｉｄｏ阻害剤とｔｄｏ阻害剤としての複素環化合物 |
| BR112017024331A2 (pt) * | 2015-05-15 | 2018-07-24 | Gilead Sciences, Inc. | composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto |
| GB2548542A (en) * | 2015-06-16 | 2017-09-27 | Redx Pharma Plc | Compounds |
| CN105037371A (zh) * | 2015-06-30 | 2015-11-11 | 西华大学 | 一种氘代的吲哚胺-2,3-双加氧酶抑制剂 |
| EP3954369B1 (en) | 2015-07-24 | 2025-08-20 | Lumos Pharma, Inc. | Salts and prodrugs of 1-methyl-d-tryptophan |
| TW201730190A (zh) | 2015-12-24 | 2017-09-01 | Genentech Inc | Ｔｄｏ２抑制劑 |
| CN107056785B (zh) * | 2016-01-02 | 2021-06-22 | 杭州英创医药科技有限公司 | 作为ido和tdo抑制剂的杂环化合物 |
| AU2017215424A1 (en) * | 2016-02-02 | 2018-08-09 | Emcure Pharmaceuticals Limited | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer |
| CN112898309A (zh) * | 2016-02-19 | 2021-06-04 | 正大天晴药业集团股份有限公司 | 作为免疫调节剂的三并环化合物 |
| CN108884104B (zh) * | 2016-02-19 | 2021-01-15 | 正大天晴药业集团股份有限公司 | 作为免疫调节剂的三并环化合物 |
| WO2017149469A1 (en) | 2016-03-03 | 2017-09-08 | Emcure Pharmaceuticals Limited | Heterocyclic compounds useful as ido and/or tdo modulators |
| BR112018071602B1 (pt) * | 2016-04-29 | 2024-02-27 | Iomet Pharma Ltd. | Compostos de imidazopiridina substituídos, sua composição e seus usos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3- dioxigenase |
| WO2017198159A1 (zh) * | 2016-05-16 | 2017-11-23 | 鲁南制药集团股份有限公司 | 含桥环的咪唑衍生物 |
| CN107383012B (zh) * | 2016-05-16 | 2021-09-28 | 鲁南制药集团股份有限公司 | 含二环的咪唑醇衍生物 |
| CN107663159A (zh) * | 2016-07-29 | 2018-02-06 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| WO2018053529A1 (en) | 2016-09-19 | 2018-03-22 | University Of South Florida | Method of targeting oncolytic viruses to tumors |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| EP3515914A4 (en) | 2016-09-24 | 2020-04-15 | BeiGene, Ltd. | INNOVATIVE 5- OR 8-SUBSTITUTED IMIDAZO [1,5-A] PYRIDINE AS SELECTIVE INHIBITORS OF INDOLEAMINE AND / OR TRYPTOPHANE-2,3-DIOXYGENASES |
| BR112019006652A2 (pt) | 2016-10-13 | 2019-07-02 | Juno Therapeutics Inc | métodos e composições para imunoterapia envolvendo moduladores da via metabólica do triptofano |
| TW201815793A (zh) * | 2016-10-21 | 2018-05-01 | 江蘇恆瑞醫藥股份有限公司 | 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法 |
| CN108203438B (zh) * | 2016-12-20 | 2021-09-28 | 深圳微芯生物科技股份有限公司 | 具有吲哚胺2,3-双加氧酶抑制活性的稠合咪唑化合物 |
| SMT202100573T1 (it) | 2016-12-22 | 2021-11-12 | Calithera Biosciences Inc | Composizioni e metodi per l'inibizione dell'attivita' dell'arginasi |
| JP2020506895A (ja) | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
| EP3645533B1 (en) | 2017-06-28 | 2025-03-26 | Genentech, Inc. | Tdo2 and ido1 inhibitors |
| US11827639B2 (en) | 2017-06-28 | 2023-11-28 | Genentech, Inc. | TDO2 and IDO1 inhibitors |
| CN109384791B (zh) * | 2017-08-09 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法 |
| JP6934562B2 (ja) * | 2017-08-22 | 2021-09-15 | ギリアード サイエンシーズ， インコーポレイテッド | 治療用複素環式化合物 |
| MA50254A (fr) * | 2017-09-15 | 2020-07-22 | Taiho Pharmaceutical Co Ltd | Agent prophylactique et/ou thérapeutique pour des maladies impliquant l'expression de l'ido |
| WO2019078246A1 (ja) * | 2017-10-19 | 2019-04-25 | 一般社団法人ファルマバレープロジェクト支援機構 | Ｉｄｏ／ｔｄｏ阻害剤 |
| CN111386114A (zh) | 2017-11-25 | 2020-07-07 | 百济神州有限公司 | 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑 |
| EP3697423A4 (en) | 2018-01-05 | 2021-08-11 | Dicerna Pharmaceuticals, Inc. | REDUCED EXPRESSION OF BETA-CATENIN AND IDO TO POTENTIALIZE IMMUNOTHERAPY |
| AU2019239952A1 (en) | 2018-03-20 | 2020-10-08 | Plexxikon Inc. | Compounds and methods for IDO and TDO modulation, and indications therefor |
| WO2020018670A1 (en) | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| KR102833434B1 (ko) * | 2018-09-27 | 2025-07-15 | 쉔젠 칩스크린 바이오사이언스 씨오., 엘티디. | 인돌아민-2,3-디옥시게나아제 억제 활성을 갖는 퀴놀린 유도체 |
| EP3856178B1 (en) | 2018-09-28 | 2026-03-11 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
| WO2020065614A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| MX2022003819A (es) | 2019-09-30 | 2022-05-11 | Janssen Pharmaceutica Nv | Ligandos de pet de mgl radiomarcados. |
| BR112022019077A2 (pt) | 2020-03-26 | 2022-12-27 | Janssen Pharmaceutica Nv | Moduladores da monoacilglicerol lipase |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| WO2022184930A2 (en) | 2021-03-05 | 2022-09-09 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH516573A (de) * | 1967-08-15 | 1971-12-15 | Sandoz Ag | Verfahren zur Herstellung von 5-Hydroxy-5-phenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindolen |
| US5807892A (en) | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
| WO1999029310A2 (en) | 1997-12-05 | 1999-06-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of t cell-mediated immunity by tryptophan and its analogs |
| EP1501918A4 (en) | 2002-04-12 | 2006-03-29 | Med College Georgia Res Inst | ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE |
| AU2003234567A1 (en) * | 2002-05-15 | 2003-12-02 | Janssen Pharmaceutica N.V. | N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors |
| WO2004094409A1 (en) | 2003-03-27 | 2004-11-04 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use |
| DE102007020493A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Amid-Derivate |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| JP2011518841A (ja) * | 2008-04-24 | 2011-06-30 | ニューリンク ジェネティクス， インコーポレイテッド | Ｉｄｏ阻害剤 |
| US8541595B2 (en) * | 2008-11-13 | 2013-09-24 | Merch Sharp & Dohme Corp. | Imidazoisoindole neuropeptide S receptor antagonists |
| US8722720B2 (en) * | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| JP2012037986A (ja) | 2010-08-04 | 2012-02-23 | Canon Inc | 画像形成装置及びその制御方法と画像形成システム |
| NO2694640T3 (https=) * | 2011-04-15 | 2018-03-17 |
-
2014
- 2014-03-10 SG SG11201507255QA patent/SG11201507255QA/en unknown
- 2014-03-10 KR KR1020157025259A patent/KR20150126623A/ko not_active Withdrawn
- 2014-03-10 CA CA2902174A patent/CA2902174A1/en not_active Abandoned
- 2014-03-10 RU RU2015143990A patent/RU2667509C2/ru not_active IP Right Cessation
- 2014-03-10 PE PE2015001907A patent/PE20151593A1/es not_active Application Discontinuation
- 2014-03-10 SG SG10201707545XA patent/SG10201707545XA/en unknown
- 2014-03-10 US US14/774,450 patent/US9617272B2/en not_active Expired - Fee Related
- 2014-03-10 CN CN201480015368.3A patent/CN105189466A/zh active Pending
- 2014-03-10 WO PCT/US2014/022680 patent/WO2014159248A1/en not_active Ceased
- 2014-03-10 MA MA38493A patent/MA38493B1/fr unknown
- 2014-03-10 MX MX2015011385A patent/MX361375B/es active IP Right Grant
- 2014-03-10 JP JP2016501035A patent/JP6093903B2/ja not_active Expired - Fee Related
- 2014-03-10 EP EP14722814.2A patent/EP2976332B1/en not_active Not-in-force
- 2014-03-10 AU AU2014241079A patent/AU2014241079C1/en not_active Ceased
- 2014-03-10 EP EP18152869.6A patent/EP3366678A1/en not_active Withdrawn
- 2014-03-10 BR BR112015022588A patent/BR112015022588A2/pt not_active Application Discontinuation
- 2014-10-03 UA UAA201510014A patent/UA118103C2/uk unknown
-
2015
- 2015-08-25 PH PH12015501866A patent/PH12015501866A1/en unknown
- 2015-09-01 IL IL241027A patent/IL241027A0/en unknown
- 2015-09-11 CL CL2015002649A patent/CL2015002649A1/es unknown
- 2015-09-14 SA SA515361127A patent/SA515361127B1/ar unknown
- 2015-09-14 CR CR20150485A patent/CR20150485A/es unknown
-
2016
- 2016-08-01 CL CL2016001940A patent/CL2016001940A1/es unknown
- 2016-11-14 JP JP2016221202A patent/JP6352368B2/ja not_active Expired - Fee Related
- 2016-11-17 ZA ZA2016/07948A patent/ZA201607948B/en unknown
-
2017
- 2017-02-16 US US15/434,414 patent/US9981973B2/en not_active Expired - Fee Related
- 2017-03-13 AU AU2017201693A patent/AU2017201693A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501866A1 (en) | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | |
| MX2013012021A (es) | Derivados de imidazol fusionados utiles como inhibidores de indoleamina 2-3 dioxigenasa (ido). | |
| GEP20217247B (en) | Indole derivatives for use in medicine | |
| PH12015502028A1 (en) | Ido inhibitors | |
| PH12017502079A1 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| MX2016000295A (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
| MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
| MX376008B (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| NZ708382A (en) | Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents | |
| MX2017015938A (es) | Inhibidores de ezh2 para el tratar linfomas. | |
| MX2016002075A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| NZ729643A (en) | Combination therapy for treating cancer | |
| MY166171A (en) | Aryl- or heteroaryl-substituted benzene compounds | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| EA201591599A1 (ru) | Ингибиторы ido | |
| MX2015017486A (es) | Inhibidores de indolamina 2,3-dioxigenasa (dio). | |
| MX2013011922A (es) | Compuestos de benceno substituido. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| MX2015014181A (es) | 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| TW201613578A (en) | Pharmaceutical combinations | |
| PH12017502046A1 (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| CL2016001361A1 (es) | Regimen de dosificación para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa | |
| HK1168106A (en) | Imidazole derivatives as ido inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |